These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21524565)

  • 41. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
    Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
    Cunningham AL; Heineman T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-10. PubMed ID: 28486850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccines for older adults.
    Lam S; Jodlowski TZ
    Consult Pharm; 2009 May; 24(5):380-91. PubMed ID: 19555147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Varicella-zoster vaccine.
    Senanayake SN
    N Engl J Med; 2007 Jul; 357(1):89-90. PubMed ID: 17615639
    [No Abstract]   [Full Text] [Related]  

  • 49. [Varicella vaccination: who should be vaccinated these days?].
    Hügle B; Suchowerskyj P; Schuster V
    MMW Fortschr Med; 2005 Feb; 147(8):31-2, 34-5. PubMed ID: 18441563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
    Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
    N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus.
    Hata A; Inoue F; Yamasaki M; Fujikawa J; Kawasaki Y; Hamamoto Y; Honjo S; Moriishi E; Mori Y; Koshiyama H
    J Infect; 2013 Sep; 67(3):215-9. PubMed ID: 23603250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zoster vaccine live (Oka/Merck).
    Robinson DM; Perry CM
    Drugs Aging; 2006; 23(6):525-31; discussion 532-3. PubMed ID: 16872235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating Physician Attitudes and Practices Regarding Herpes Zoster Vaccination.
    Tsui E; Gillespie C; Perskin M; Zabar S; Wu M; Cohen EJ
    Cornea; 2018 Aug; 37(8):947-951. PubMed ID: 29578865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Herpes zoster vaccine. Poorly effective in those who need it most.
    Prescrire Int; 2012 Dec; 21(133):291. PubMed ID: 23373094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. When zoster hits close to home: Impact of personal zoster awareness on zoster vaccine uptake in the U.S.
    Harpaz R; Leung J
    Vaccine; 2017 Jun; 35(27):3457-3460. PubMed ID: 28528766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of herpes zoster vaccine programme.
    Drug Ther Bull; 2018 Oct; 56(10):115. PubMed ID: 30254060
    [No Abstract]   [Full Text] [Related]  

  • 57. Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease.
    Tseng HF; Luo Y; Shi J; Sy LS; Tartof SY; Sim JJ; Hechter RC; Jacobsen SJ
    Clin Infect Dis; 2016 Feb; 62(4):462-7. PubMed ID: 26671505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
    Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
    Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Commentary regarding: Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. H Lal, AL Cunningham, O Godeaux et al., N Engl J Med 372:2087-2096, 2015.
    Yancey KB
    Dermatol Ther; 2016 Sep; 29(5):300-301. PubMed ID: 26798973
    [No Abstract]   [Full Text] [Related]  

  • 60. Immune responses to zoster vaccines.
    Levin MJ; Weinberg A
    Hum Vaccin Immunother; 2019; 15(4):772-777. PubMed ID: 30676834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.